88 results about "Immune disorder" patented technology

Pet food compositions, and particularly, pet food compositions comprising fish collagen hydrolysate are disclosed herein. Also disclosed herein are methods of treating an immune disorder, such as atopic dermatitis in a companion animal in need thereof and methods of alleviating at least one of pruritus, erythema, or alopecia in a companion animal with atopic dermatitis.

The invention discloses a black phosphorus hydrogel microneedle patch loaded with trained mesenchymal stem cells as well as a preparation method and application of the black phosphorus hydrogel microneedle patch, and belongs to the technical field of biological medicines. The micro-needle patch comprises a hydrogel substrate layer loaded with black phosphorus nanosheets and a hydrogel needle tip part for packaging the stem cells. The mesenchymal stem cells are subjected to combined domestication with low oxygen and high active oxygen, so that the anti-oxidative stress, anti-inflammatory and angiogenesis promoting capabilities of the mesenchymal stem cells are remarkably enhanced. After the patch is subcutaneously delivered, the black phosphorus component can efficiently remove bacteria and reduce drug resistance; after being domesticated, the stem cells can adapt to the immune microenvironment of the wound surface, and the immune regulation, inflammation inhibition and tissue regeneration promotion are synergistically realized by continuously releasing anti-inflammatory and angiogenesis promoting factors, so that the refractory wound surface caused by immune disorders such as systemic lupus erythematosus (SLE) and the like is effectively treated. The invention provides an innovative treatment strategy for chronic inflammatory wound healing.

The present invention relates to an oligonucleotide comprising from 10 to 25 nucleotides wherein at least one of said nucleotides is modified, and the oligonucleotide hybridizes with the pre-mRNA of the neurociliin 1 (NRP1, CD304) of SEQ ID NO. 366 (GRCh38p13Chr 1033177492-33336262-1) or with the mRNA of the NRP1 of SEQ ID NO. 367 (RefSeq ID NM003873.6). The invention also relates to a pharmaceutical composition comprising the oligonucleotide. The pharmaceutical composition and the oligonucleotide are for use in a method of preventing and / or treating cancer, ophthalmic disease, autoimmune disorder and / or immune disorder.

Disclosed herein are boronated amino acid compositions comprising tyrosine derivatives TC220 and TC221 and improved methods of making TC220 and TC221. Thus, the TC220 and / or TC221 can be expanded to commercial scale and administered to patients as neutron trapping agents, and methods of treating cancer, immune disorders, and other diseases by utilizing a neutron capture therapy pattern are provided.

The present invention relates to compositions and methods for subpopulation-specific modulation of cell function and for treating repeat expansion disorders comprising genetic, degenerative, neurological and cellular diseases, including immune disorders. Also provided are research kits for subpopulation-specific modulation of protein activity and the corresponding potential to discover novel therapeutic compositions. More specifically, the disclosed compositions and methods selectively up- or downregulate at least a first population of a cellular protein or therapeutic target with minimal or negligible effect on the activity of at least a second population of the cellular protein or therapeutic target.

The present invention relates to the field of biomedicine, and more specifically, to a humanized anti-human PD-L1 antibody or antigen-binding fragment thereof and its use. The antibody or antigen-binding fragment thereof of the present invention has high affinity and strong binding specificity for PD-L1, effectively blocks the binding of PD-L1 to PD-1 and CD80, stimulates cytokine production, and exhibits significant anti-tumor effects. It can be used alone or in combination with other agents to prevent or treat immune disorders or tumor-related diseases.

Tolerogenic liposome-based compositions and uses thereof for treating immune disorders. The compositions include two populations of liposomes. The first population of liposomes has a size in the range from 2 to 200 nm, and the second population of liposomes has a size in the range from 500 to 2000 nm. The liposomes of the first and second populations carry one or more antigens. The liposomal membrane of each liposome in the first and second liposome populations include phosphatidylserine in an amount ranging from 20 to 60% by weight with respect to the total composition of the liposome's membrane.

The invention discloses a traditional Chinese medicine composition for treating sepsis as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from 1-15 parts of sulfur, 3-25 parts of calamitas urinae hominis, 1-20 parts of wine-treated rhubarb, 10-30 parts of fructus cannabis, 10-50 parts of radix bupleuri, 5-30 parts of scutellaria baicalensis, 5-25 parts of folium isatidis, 5-25 parts of peach kernels, 5-30 parts of salvia miltiorrhiza, 5-30 parts of angelica sinensis, 5-30 parts of sophora flower charcoal, 5-25 parts of fructus gardeniae praeparatus and 5-60 parts of wine-treated fructus corni. According to the invention, through a combined mode of'monarch drug targeted oral administration and synergistic decoction of minister, assistant and guide drugs', the whole-course intervention of'upstream inhibition, midstream blocking and downstream regulation 'on sepsis immune disorder can be realized, meanwhile, the functions of warming yang, dispelling cold, cooling blood and detoxifying are taken into account, and the pro-inflammatory / anti-inflammatory balance is successfully recovered to a physiological state; the action mode is superior to that of a traditional single anti-inflammatory strategy and a traditional Chinese medicine application mode of whole-prescription decoction. In a standard animal model, the traditional Chinese medicine composition definitely shows the dose-dependent extremely remarkable effects of anti-inflammation, immunoregulation, multi-organ protection and overall condition improvement, the curative effect of a high-dose group of the traditional Chinese medicine composition is equivalent to that of a classic potent medicine, and the traditional Chinese medicine composition has more advantages in the aspects of recovering immune homeostasis, warming yang and strengthening the body resistance.

The invention belongs to the field of food, particularly relates to a nutritional composition and application thereof in improving immune disorder, and more particularly relates to application of the nutritional composition in preparing food for improving filial generation body inflammatory factor level disorder caused by maternal immune activation. The nutritional composition comprises essential active ingredients shown as the following (i) and (ii): (i) a neutral fucosylated breast milk oligosaccharide, (ii) a neutral non-fucosylated breast milk oligosaccharide; wherein the neutral fucosylated breast milk oligosaccharide at least comprises 2 '-fucosylated lactose, and the neutral non-fucosylated breast milk oligosaccharide at least comprises lactose-N-neotetraose; in addition, in the nutritional composition, the mass ratio of the lactose-N-neotetraose to the 2 '-fucosyllactose is 1: (1-8), and the 2'-fucosyllactose and the lactose-N-neotetraose can achieve a synergistic effect to regulate filial generation immunity.

To provide new and improved methods of treating cancer, immune disorders, and other diseases utilizing borylated amino acids and neutron capture therapy (NCT).SOLUTION: Disclosed herein are borylated amino acid ("BAA") compositions and methods of making BAAs. Accordingly, BAAs can be administered to patients as neutron capture agents and can provide methods of treating cancer, immune disorders, and other diseases by utilizing neutron capture therapy modalities. The invention described herein relates to the field of boron neutron capture therapy (BNCT). In particular, the present invention relates to borylated amino acid ("BAA") or ("BAAs") compositions that can be used as a vehicle for neutron capture therapy in humans. The invention further relates to the treatment of cancer and other immune disorders and diseases.SELECTED DRAWING: None

This invention discloses a class of indole derivatives containing or without heteroatoms (such as nitrogen heteroatoms) and their pharmaceutical compositions that can be used as PI3Kδ kinase inhibitors, and can be used to treat diseases, conditions or symptoms related to PI3Kδ inhibition, including immune disorders, cancer and cardiovascular diseases.

Disclosed herein are 3,4-didehydro- and 3′-deoxy-3,4-didehydro-compounds and pharmaceutical compositions thereof. Methods of use of these pharmaceutical compositions include those for treating diseases including virus-induced diseases, cancer, autoimmune diseases, immune disorders, and bacterial-associated diseases or infections, or combinations thereof. Examples of viral-induced diseases include viral infections by RNA or DNA viruses, for example SAR-CoV-2, EBV, BKV, JCV and HCMV.

The present invention relates to compounds of formula (I) and pharmaceutically acceptable compositions thereof useful as toll-like receptor 7 / 8 (TLR7 / 8) antagonists.SOLUTION: In Formula (I), ring A is aryl or heteroaryl; ring B is aryl or heteroaryl; and X is C (R4) 2, O, NR4, S, S (R4), or S (R4) 2.SELECTED DRAWING: None

The invention provides a method for preparing gamma delta T cells and application of the gamma delta T cells. The gamma delta T cells are useful for the treatment of various cancers, infectious diseases and immune disorders. Also provided are methods for expanding a population of gamma delta T cells to a therapeutically effective amount. The gamma delta T cells may be administered to a subject having any MHC haplotype.

The invention belongs to the field of nutrient substance research, and particularly relates to a nutrient composition for improving brain development. The nutritional composition provided by the invention comprises necessary active ingredients shown in the following (i) and (ii): (i) lactose-N-neotetraose, (ii) 1, 2-diacyl-sn-glycerol-3-phosphorylcholine, and (iii) 1, 2-diacyl-sn-glycerol-3-phosphorylcholine. The nutritional composition comprises lactose-N-neotetraose and 1, 2-diacyl-sn-glycerol-3-phosphorylcholine, and in the nutritional composition, the mass ratio of the lactose-N-neotetraose to the 1, 2-diacyl-sn-glycerol-3-phosphorylcholine is 1: (0.010-2.5). The research shows that the combination of the lactose-N-neotetraose and the 1, 2-diacyl-sn-glycerol-3-phosphorylcholine can be used for improving offspring brain immune disorder and / or nervous system dysplasia caused by maternal immune activation, and the lactose-N-neotetraose and the 1, 2-diacyl-sn-glycerol-3-phosphorylcholine have a synergistic interaction effect.

Pet food compositions, and particularly, pet food compositions comprising fish collagen hydrolysate are disclosed herein. Also disclosed herein are methods of treating an immune disorder, such as atopic dermatitis in a companion animal in need thereof and methods of alleviating at least one of pruritus, erythema, or alopecia in a companion animal with atopic dermatitis.

Pet food compositions, and particularly, pet food compositions comprising fish collagen hydrolysate are disclosed herein. Also disclosed herein are methods of treating an immune disorder, such as atopic dermatitis in a companion animal in need thereof and methods of alleviating at least one of pruritus, erythema, or alopecia in a companion animal with atopic dermatitis.

The present invention refers to an oligonucleotide consisting of a core sequence of ATATTTAGGTCCAGCG (SEQ ID NO:1) or AATATTTAGGTCCAGCG (SEQ ID NO:2) and at least one additional nucleotide at the 3´-end and optionally at least one additional nucleotide at the 5´-end. At least one of the nucleotides of the oligonucleotide is modified, and the oligonucleotide binds to pre-mRNA of neuropilin 1 (NRP1, CD304). The invention is further directed to a pharmaceutical composition comprising such oligonucleotide. The pharmaceutical composition and the oligonucleotide are for use in a method of preventing and / or treating cancer, an ophthalmic disease, an autoimmune disorder and / or an immune disorder.

A method and compositions of matter for treating or preventing an auto-immune disorder or immune response in a patient, that includes providing a therapeutic dose to the patient of a substituted indole compound having at least one substitution, wherein the substituted indole compound has only one thiol group, and wherein the ring the thiol group is attached to only contains one N or O atom.

To provide an antitumor antagonist comprising a first targeting domain comprising a mutated TGFβ1-R11 extracellular domain (mutated ECD); and an immunoglobulin scaffold having an amino terminus and a carboxy terminus.SOLUTION: The present disclosure relates to an antitumor antagonist comprising a first targeting domain comprising a mutated TGFβ1-R11 extracellular domain (mutated ECD); and an immunoglobulin scaffold having an amino terminus and a carboxy terminus, the one or more mutations reducing proteolytic cleavage of the antitumor antagonist. Also disclosed are methods for treating proliferative disorders, infections, and immunological disorders with the antitumor antagonists described herein.SELECTED DRAWING: Figure 20

The invention relates to Interleukin-2 (IL-2) variants for the prevention or treatment of immune disorders, including with no limitations allergic, autoimmune, chronic or acute inflammatory and infectious diseases; graft-versus-host disease; graft rejection and cancer. The invention also relates to the use of said IL-2 variants for the screening of anti-IL-2 antibodies with pro-T-effector or pro-T-regulatory cell activity.

Disclosed herein is are methods of preventing, reducing or inhibiting a viral or immune disorder, comprising administering to a subject at risk or that has acquired a viral or immune disorder an effective amount of a composition comprising a polypeptide derived from a reactive center loop of a serine protease inhibitor or a biologically active variant thereof, wherein the subject has not been administered antibiotics within at least one day of administering the composition. Also disclosed are compositions and kits for preventing, reducing or inhibiting a viral or immune disorder.

Disclosed herein are formulated and / or co-formulated lipid nanoparticles (LNPs) and solid lipid nanoparticles (SLNPs) comprising TB prodrugs and methods of making the LNPs and the SLNPs. TB prodrug compositions comprising a drug moiety, a lipid moiety, and a linking unit, inhibit ALK5. The TB prodrugs can be formulated and / or co-formulated into liposomes or solid lipid nanoparticles to provide methods of treating cancer, immune disorders, and other diseases by taking advantage of targeted drug delivery vehicles.

Provided herein are methods of preparing adoptive cell compositions and uses thereof. The adoptive cell compositions are useful in the treatment of various cancers, infectious diseases, and immune disorders.

The present application relates to substituted pyrrole carboxamide derivatives of Formula (I) that modulate the activity of the cell division cycle 7-related kinase (Cdc7). Accordingly, the compounds of the present application are useful in the treatment of diseases associated with dysregulated kinase activity, such as cancer, cell proliferative disorders, viral infections, immune disorders, neurodegenerative disorders, cardiovascular diseases, and bone-related diseases. The present application also provides methods for making these compounds, pharmaceutical compositions comprising these compounds, and their medical uses.

The application belongs to the technical field of biology and specifically relates to a kind of mesenchymal stem cell aggregate jointly enabled by matrix and cytokine and application, the aggregate is by mesenchymal stem cell in the medium added cell culture matrix and IGF-1 is cultivated and obtains pretreated mesenchymal stem cell, continue in 3D cell culture system and obtain by generation culture, the calcium adhesion cell culture matrix is prepared by 1-3 parts hE-cad-Fc and 1-3 parts hN-cad-Fc;The aggregate structure obtained is complete, boundary is clear, high expression intracellular endogenous calcium adhesion and phosphorylated IGF-1 receptor, the curative effect of complex etiology, refractory, recurrent immune disorder diseases is significantly improved, such as systemic sclerosis, xerophthalmia and systemic lupus erythematosus.

The hybrid Fc proteins of this invention include IgG and IgM Fc components. The IgG Fc component includes at least a portion of a hinge region and CH2 and CHS regions. The IgM component includes Cμ3 and Cμ4 regions of a Cμ constant region. The hybrid Fc proteins can form duplexes by interchain disulfide bonding between cysteines in their hinge regions. The hybrid Fc proteins can be used for treating immune disorders mediated by endogenous IgG, such as those previously treated with intravenous immunoglobulin.

Provided herein are compositions comprising Ig protease fusion proteins and methods related to the compositions. Also provided herein are compositions and methods for therapeutic treatment, such as the therapeutic treatment of autoimmune diseases, allergies, or other immune disorders, or in combination with the administration of another therapeutic agent, which utilize such Ig protease fusion proteins.

Provided herein, inter alia, are compositions and methods including recombinant oncolytic viruses expressing human IL-15 and human IL-15Rα-sushi domain for the treatment of cancer and immune disorders. The recombinant oncolytic viruses may be used in combination with immune cells expressing chimeric antigen receptors (CAR) targeting EGFR and EGFR mutants.

The invention relates to the technical field of molecular biology, in particular to application of RIPK3 gene mutation as a detection target and a detection reagent. An experiment shows that an individual with heterozygote RIPK3 mutation (c.400Cgt; A, p.Gln134Lys) shows the symptom of a Still disease sample self-inflammatory disease, and a potential relation exists between the variation and immune disorder, and is characterized in that necroptosis sensitivity is increased and an inflammatory signal is amplified, so that a pro-inflammatory environment is caused. According to the invention, the relation between RIPK3 variation and the expression of the self-inflammatory disease of the Stetier disease sample is established, the understanding of people on the molecular basis of the self-inflammatory disease of the Stetier disease sample is expanded, and the importance of RIPK3 in human immune homeostasis is emphasized.